Free Trial
NASDAQ:MIRM

Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

Mirum Pharmaceuticals logo
$49.93 +0.84 (+1.71%)
Closing price 07/3/2025 02:30 PM Eastern
Extended Trading
$49.66 -0.27 (-0.55%)
As of 07/3/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Key Stats

Today's Range
$49.01
$50.41
50-Day Range
$40.80
$51.11
52-Week Range
$33.64
$54.23
Volume
216,684 shs
Average Volume
465,058 shs
Market Capitalization
$2.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.50
Consensus Rating
Buy

Company Overview

Mirum Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

MIRM MarketRank™: 

Mirum Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 955th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Mirum Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Mirum Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.43) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mirum Pharmaceuticals is -31.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mirum Pharmaceuticals is -31.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mirum Pharmaceuticals has a P/B Ratio of 10.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mirum Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    14.66% of the float of Mirum Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Mirum Pharmaceuticals has recently increased by 2.64%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Mirum Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Mirum Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.66% of the float of Mirum Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Mirum Pharmaceuticals has recently increased by 2.64%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Mirum Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Mirum Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,624.00 in company stock.

  • Percentage Held by Insiders

    14.36% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Mirum Pharmaceuticals' insider trading history.
Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIRM Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
Mirum Pharmaceuticals Inc.
See More Headlines

MIRM Stock Analysis - Frequently Asked Questions

Mirum Pharmaceuticals' stock was trading at $41.35 on January 1st, 2025. Since then, MIRM shares have increased by 20.7% and is now trading at $49.93.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. The company's revenue for the quarter was up 61.2% compared to the same quarter last year.
Read the conference call transcript
.

Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Last Earnings
5/14/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MIRM
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$65.50
High Stock Price Target
$77.00
Low Stock Price Target
$49.00
Potential Upside/Downside
+31.2%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$87.94 million
Pretax Margin
-20.01%

Debt

Sales & Book Value

Annual Sales
$336.89 million
Price / Cash Flow
N/A
Book Value
$4.70 per share
Price / Book
10.62

Miscellaneous

Free Float
42,422,000
Market Cap
$2.47 billion
Optionable
Optionable
Beta
0.97
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:MIRM) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners